Evidence map›Paper›PMID 38280079›Full record

ArticleCancer immunology, immunotherapy : CII2024

Novel mechanism of drug resistance triggered by tumor-associated macrophages through Heat Shock Factor-1 activation.

Alina D Nikotina, Snezhana A Vladimirova, Nadezhda E Kokoreva, Valeria A Nevdakha, Vladimir F Lazarev, Liubov S Kuznetcova, Elena Y Komarova, Roman V Suezov, Sergei Efremov, Elizaveta Leonova and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma.Journal of experimental & clinical cancer research : CR · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Alina D Nikotina *Laboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Snezhana A Vladimirova *Laboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Nadezhda E Kokoreva *Laboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Valeria A NevdakhaLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Vladimir F LazarevLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Liubov S KuznetcovaLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Elena Y KomarovaLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Roman V SuezovLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Sergei EfremovSaint-Petersburg State University Hospital, 190103, St. Petersburg, Russia.
Elizaveta LeonovaSaint-Petersburg State University Hospital, 190103, St. Petersburg, Russia.
Viktor G KartsevInterBioScreen, Chernogolovka, Moscow, 142432, Russia.
Nikolay D AksenovLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Boris A MargulisLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia.
Irina V GuzhovaLaboratory of Cell Protection Mechanisms, Institute of Cytology of Russian Academy of Sciences, St. Petersburg, 194064, Russia. irina.guzh@gmail.com.ORCID http://orcid.org/0000-0002-8775-7713
Institute of Cytology · RUSt Petersburg University · RUPhilipps University of Marburg · DE

Funding

Russian Science Foundation 19-74-20161
6 · The paper itself

Abstract

Macrophages constitute a major part of tumor microenvironment, and most of existing data demonstrate their ruling role in the development of anti-drug resistance of cancer cell. One of the most powerful protection system is based on heat shock proteins whose synthesis is triggered by activated Heat Shock Factor-1 (HSF1); the inhibition of the HSF1 with CL-43 sensitized A549 lung cancer cells to the anti-cancer effect of etoposide. Notably, analyzing A549 tumor xenografts in mice we observed nest-like pattern of co-localization of A549 cells demonstrating enhanced expression of HSF1 with macrophages, and decided to check whether the above arrangement has a functional value for both cell types. It was found that the incubation of A549 or DLD1 colon cancer cells with either human monocytes or THP1 monocyte-like cells activated HSF1 and increased resistance to etoposide. Importantly, the same effect was shown when primary cultures of colon tumors were incubated with THP1 cells or with human monocytes. To prove that HSF1 is implicated in enhanced resistance caused by monocytic cells, we generated an A549 cell subline devoid of HSF1 which did not respond to incubation with THP1 cells. The pharmacological inhibition of HSF1 with CL-43 also abolished the effect of THP1 cells on primary tumor cells, highlighting a new target of tumor-associated macrophages in a cell proteostasis mechanism.

Indexed as

DNA-Binding ProteinsTranscription FactorsAnimalsCell Line, TumorDrug ResistanceEtoposideHeat-Shock ResponseHeat Shock Transcription FactorsHumansMiceTumor-Associated MacrophagesDNA-Binding ProteinsEtoposideHeat Shock Transcription FactorsHSF1 protein, humanTranscription FactorsCancer drug resistanceHSF1MonocytesTHP1Tumor microenvironment

Identifiers

PMID38280079
PMCPMC10821977
OpenAlexW4391278346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.